Celularity Inc. Reports Significant Variation in Net Revenues and Maintains Investment Focus Despite Short-Term Profitability Challenges

Reuters
05-09
<a href="https://laohu8.com/S/CELU">Celularity Inc.</a> Reports Significant Variation in Net Revenues and Maintains Investment Focus Despite Short-Term Profitability Challenges

Celularity Inc. has reported its actual financial results for the year ended December 31, 2024. The company's total net revenues increased significantly to $54.220 million, compared to $22.771 million in the previous year. This growth was driven by a rise in product sales, which reached $35.336 million, up from $13.149 million the previous year. Additionally, revenues from licenses, royalties, and other sources grew to $13.744 million from $4.181 million. Despite the increase in revenues, Celularity Inc. continues to face financial challenges, as indicated by its accumulated deficit of $899.683 million, compared to $841.791 million the previous year. These results highlight the company's ongoing efforts to enhance its revenue streams through increased product sales and licensing agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-009319), on May 08, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10